Ranibizumab is a recombinant humanized monoclonal antibody fragment directed against vascular endothelial growth factor A (VEGF-A). Unlike a conventional small-molecule API, Ranibizumab is a complex biological molecule requiring protein-specific characterization and biological potency testing.
Ranibizumab has an approximate molecular weight of 48 kDa and is designed to bind VEGF-A, thereby inhibiting VEGF-mediated vascular permeability and abnormal blood-vessel growth.
Ranibizumab is the antigen-binding fragment of a humanized antibody and does not contain the Fc region. EMA's scientific assessment describes Ranibizumab as approximately 48 kDa and confirms that it binds biologically active VEGF isoforms including VEGF165, VEGF121 and VEGF110.
| Parameter | Details |
|---|---|
| Product | Ranibizumab |
| CAS | 347396-82-1 |
| UNII | ZL1R02VT79 |
| Molecular Type | Recombinant antibody fragment |
| Isotype | Humanized IgG1-kappa Fab |
| Approx. Molecular Weight | 48 kDa |
| Target | VEGF-A |
| Biological Class | Anti-VEGF |
| Pharmaceutical Category | Biological API |
| Route in approved products | Intravitreal |
| Dosage form | Sterile solution for injection |
EMA identifies Ranibizumab as the active substance in Lucentis and multiple approved biosimilars, including Ranivisio, Byooviz and newer products authorized in 2026.
Ranibizumab is used in pharmaceutical products for:
These indications are reflected in current EMA product information for Ranibizumab products.
Because Ranibizumab is a biological API, quality control focuses on protein-specific critical quality attributes. EMA assessment documents describe testing for:
Peptide mapping and VEGF-A165 binding by ELISA are among the identity/characterization approaches described in recent regulatory documentation.
Manufacturing Ranibizumab requires recombinant biological production followed by purification and extensive characterization. Unlike a conventional chemical API, control of molecular size, aggregation, charge heterogeneity, protein concentration, biological activity and process-related impurities is essential.
For finished Ranibizumab injection products, current EMA product information specifies refrigerated storage at 2–8°C and protection from freezing.
For the bulk drug substance, storage conditions should be taken from the applicable validated manufacturer specification rather than automatically applying the finished-product storage condition.
Typical Ranibizumab biological API documentation can include:
Ranibizumab requires a biological-product quality system designed around protein identity, purity, molecular heterogeneity and biological activity. Appropriate validated analytical methods and control of critical quality attributes are essential for consistent pharmaceutical-quality material.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.2% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150–200°C |